GIS
GILEAD SCIENCES DL-,001
Stock XETRA – Stock Market Prices, News & Analysis
Gilead Sciences est une entreprise biopharmaceutique américaine spécialisée dans le développement de traitements antiviraux, notamment pour le VIH, l'hépatite C et d'autres maladies graves.
GILEAD SCIENCES DL-,001
GIS
Gilead Sciences est une entreprise biopharmaceutique américaine spécialisée dans le développement de traitements antiviraux, notamment pour le VIH, l'hépatite C et d'autres maladies graves.
Price history of GILEAD SCIENCES DL-,001
Price history of GILEAD SCIENCES DL-,001
Performance & Momentum
Strategic Analysis
GILEAD SCIENCES DL-,001 • 2026
Gilead Sciences positions itself as a benchmark player in the U.S. biopharmaceutical sector, specializing in innovative antiviral treatments for serious diseases such as HIV and hepatitis C. Its model is based on strong clinical research capabilities and the development of high medical-impact drugs, ensuring it a strategic position in specialty pharmacology.
- Strong portfolio of proven antiviral treatments targeting highly prevalent chronic diseases
- Advanced clinical research capabilities supporting therapeutic innovation
- Established position in a dynamic U.S. market with high barriers to entry
- Notable dependence on a few major franchises, limiting revenue diversification
- Regulatory pressures and challenges related to competition from generics and biosimilars
Momentum remains strong and reflects a renewed investor interest, supported by solid performance over several years. This dynamism reflects the resilience of the business model despite an intense competitive environment, suggesting sustainable medium-term valuation potential.
Similar stocks to GILEAD SCIENCES DL-,001
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
